About: Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor
Creator	Peiris, Malik Altmeyer, Ralf Bethur, Nijaguna Pathak, Mukta Pendharkar, Vishal Sharma, Geeta Fen, Leong, Hwei Sharma, Danilal
Source	Medline; PMC
abstract	Inflammatory responses contribute to the morbidity and mortality of severe influenza. Current antiviral therapy offers limited success in treating severe influenza infection with both H1N1 and H5N1 viruses. We evaluated the effect of a neuraminidase inhibitor in combination with immunomodulatory drugs in vitro and in a mouse model of influenza A H1N1 infection by determining survival rate, lung inflammation markers and histopathology. Sertraline and rolipram significantly improved survival in mice infected with a lethal dose of influenza A H1N1 virus. Prophylactic treatment resulted in survival rates of 40% (rolipram), 30% (oseltamivir), 0% (sertraline), 100% (rolipram/oseltamivir) and 70% (sertraline/oseltamivir). Treatment in a therapeutic setting (24 h post-infection) resulted in 80% (rolipram/oseltamivir) and 40% (sertraline/oseltamivir) survival. Sertraline and rolipram had no effect on virus replication in vitro and in vivo, but significantly reduced lung inflammation. A significant reduction in cellular infiltration (10-fold) along with inflammatory cytokines monocyte chemotactic protein-1 (10-fold), interleukin-6 (5-fold) and regulated on activation normal T cell expressed and secreted (5-fold) was observed in the animals treated with the combination compared to oseltamivir alone. Lung histopathology of mice treated with combinations revealed significantly reduced consolidation, infiltration and alveolitis compared to oseltamivir alone. Rolipram and sertraline reduced H1N1 virus-induced lung inflammation and mortality. These data support further development of immunomodulatory agents for severe influenza.
has issue date	2013-08-21(xsd:dateTime)
bibo:doi	10.1038/emi.2013.52
bibo:pmid	26038487
has license	cc-by-nc-nd
sha1sum (hex)	461bd946be4c4280c46eb9a7b163e9f3da0a734a
schema:url	https://doi.org/10.1038/emi.2013.52
resource representing a document's title	Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor
has PubMed Central identifier	PMC3821288
has PubMed identifier	26038487
schema:publication	Emerg Microbes Infect
resource representing a document's body	covid:461bd946be4c4280c46eb9a7b163e9f3da0a734a#body_text
is schema:about of	named entity 'drugs' named entity 'fold' named entity 'rolipram' named entity 'reduced' named entity 'lung inflammation' named entity 'Rolipram' named entity 'lung inflammation' named entity 'selective serotonin reuptake inhibitor' covid:arg/461bd946be4c4280c46eb9a7b163e9f3da0a734a named entity 'improved' named entity 'Inflammatory' named entity 'limited' named entity 'reduction' named entity 'histopathology' named entity 'survival' named entity 'influenza' named entity 'rolipram' named entity 'Prophylactic' named entity 'neuraminidase inhibitor' named entity 'mortality' named entity 'oseltamivir' named entity 'support' named entity 'Treatment' named entity 'sertraline' named entity 'replication' named entity 'severe' named entity 'severe' named entity 'oseltamivir' named entity 'Current' named entity 'sertraline' named entity 'lung inflammation' named entity 'neuraminidase inhibitor' named entity 'mouse model' named entity 'Sertraline' named entity 'T cell' named entity 'mice' named entity 'lung inflammation' named entity 'influenza' named entity 'oseltamivir' named entity 'immunomodulatory drugs' named entity 'oseltamivir' named entity 'interleukin-6' named entity 'H1N1 virus' named entity 'cellular infiltration' named entity 'influenza virus' named entity 'antiviral' named entity 'Life Technologies' named entity 'wild-type' named entity 'lung' named entity 'morbidity' named entity 'necrosis' named entity 'interleukin (IL)-6' named entity 'mice' named entity 'viral load' named entity 'preclinical development' named entity 'oseltamivir' named entity 'influenza' named entity 'BALF' named entity 'tumor' named entity 'chronic obstructive pulmonary disease' named entity 'lung disease' named entity 'virus' named entity 'virus' named entity 'supernatant' named entity 'Influenza' named entity 'hematoxylin and eosin' named entity 'virus' named entity 'microplates' named entity 'oseltamivir' named entity 'immunomodulatory drugs' named entity 'viral replication' named entity 'oseltamivir' named entity 'non-central'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software